Takeda Pharmaceutical Company Limited
TKPHF
$28.35
$0.672.42%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.86% | -5.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.86% | -5.18% | |||
| Cost of Revenue | -10.39% | 3.04% | |||
| Gross Profit | -6.41% | -9.33% | |||
| SG&A Expenses | 9.41% | -1.70% | |||
| Depreciation & Amortization | 1.83% | -7.03% | |||
| Other Operating Expenses | -162.45% | 421.67% | |||
| Total Operating Expenses | -18.19% | 18.69% | |||
| Operating Income | 1,934.12% | -97.56% | |||
| Income Before Tax | -506.61% | -78.44% | |||
| Income Tax Expenses | -263.45% | -90.81% | |||
| Earnings from Continuing Operations | -532.85% | -74.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -24.01% | 26.51% | |||
| Net Income | -533.93% | -74.81% | |||
| EBIT | 1,934.12% | -97.56% | |||
| EBITDA | 14.96% | -56.66% | |||
| EPS Basic | -534.96% | -74.85% | |||
| Normalized Basic EPS | 344.69% | -116.73% | |||
| EPS Diluted | -534.96% | -74.43% | |||
| Normalized Diluted EPS | 344.69% | -117.01% | |||
| Average Basic Shares Outstanding | -0.21% | 0.14% | |||
| Average Diluted Shares Outstanding | -0.21% | -1.52% | |||
| Dividend Per Share | -- | -100.00% | |||
| Payout Ratio | -1.02% | 60.18% | |||